# US 2026/0077009 A1 · Compositions and methods for treating neurological disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077009 A1
- Document ID: US20260077009A1
- Status: Published application
- Kind: A1
- Application number: 19/335,945
- Filed: 2025-09-22
- Published: 2026-03-19
- Earliest claimed: 2021-10-11
- Assignees: Neurotech International Ltd
- Applicants: Neurotech International Ltd
- Inventors: Allan William Cripps; Esra Isikgel; Alexandra Elizabeth Marion Andrews; Thomas George Duthy
- Web page: https://patentgrep.com/patent/US20260077009A1

## CPC

- A61K 36/3482: {Cannabis}
- A61P 25/16: Anti-Parkinson drugs
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K 2236/15: involving mechanical treatment, e.g. chopping up, cutting or grinding
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K 2236/35: Extraction with lipophilic solvents, e.g. Hexane or petrol ether
- A61K 2236/53: Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions comprising cannabinoids. The present invention also relates to pharmaceutical compositions, dosage forms and methods of treating neurological disorders by administering the composition to a patient in need thereof.

## Claims

### Claim 1

A composition comprising the following cannabinoids:
w/w %
CBDA 40-60%;
CBD 1-5%;
CBG 1-10%;
CBDP 1-5%;
CBDB 1-5%;
CBGA 1-10%;
CBN 1-3%
and
THC <1%.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the cannabinoids are present in amounts selected from the group consisting of:
Composition 1 comprising
w/w %
CBDA 50%;
CBD 2%;
CBG 5%;
CBDP 2%;
CBDB 2%;
CBGA 5%;
CBN 3% and
THC <0.3%;
and
Composition 2 comprising
w/w %
CBDA 45%;
CBD 1%;
CBG 4%;
CBDP 1%;
CBDB 2%;
CBGA 4%;
CBN 2% and
THC <0.2%.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising an oil selected from the group consisting of: a synthetic oil; plant based oil; mineral oil; canola oil; and olive oil.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises less than 5% w/w terpenes.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition comprises less than 2% w/w organic plant material.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition comprises less than 2% w/w of plant phenols.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the cannabinoid component of the composition is selected from the group consisting of: between 1 and 500 mg/ml; between 10 and 100 mg/ml; and be at a concentration of 50 mg/ml.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the CBDA component of the composition is selected from the group consisting of: between 1 and 500 mg/ml; between 10 and 100 mg/ml; and be at a concentration of 50 mg/ml.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1)

A dosage form comprising the composition of claim 1.

### Claim 11 (depends on 10)

The dosage form of claim 10, wherein the CBDA component of the composition is selected from the group consisting of: between 1 mg and 1000 mg; between 1 mg and 500 mg; between 1 and 100 mg; less than 400 mg; less than 300 mg; less than 200 mg; and less than 100 mg.

### Claim 12 (depends on 10)

The dosage form of claim 10, wherein the CBDA component of the composition is selected from the group consisting of: 600 mg; 400 mg; 300 mg; 200 mg; 100 mg; 50 mg; 10 mg; 5 mg; 2 mg; and 1 mg.

### Claim 13 (depends on 10)

A method of treating a disorder, said method comprising administering to a patient in need thereof a therapeutically effective amount of the dosage form of claim 10.

### Claim 14 (depends on 13)

The method of claim 13, wherein the disorder is a neurological disorder.

### Claim 15 (depends on 14)

The method of claim 14, wherein the neurological disorder is selected from the group consisting of: Alzheimer's disease (AD); Parkinson's disease (PD); multiple sclerosis; amyotrophic lateral sclerosis; cerebral ischemia; traumatic brain injury; rheumatoid arthritis; chronic migraine; epilepsy; autism spectrum disorder (ASD); attention deficit hyperactivity disorder (ADHD); cerebral palsy and relevant subtypes; neuropathic pain; and depression.

### Claim 16 (depends on 1)

A process of extracting the composition of claim 1 from cannabis plant material, said process comprising the steps of:
(1) Grinding the cannabis plant material to a sufficient grind size;
(2) Contacting the grind produced by step a) with oil;
(3) Mixing the grind and oil for a sufficient time period to form a mixture;
(4) Pressing the mixture to reclaim the oil;
(5) Centrifuging the oil to further refine the oil; and
(6) Collecting the oil extract in a suitable container.

### Claim 17 (depends on 16)

A product produced from the process of claim 16.

### Claim 18 (depends on 1)

A process of extracting the composition of claim 1 from cannabis plant material, said process comprising the steps of:
(1) Grinding the cannabis plant material to a sufficient grind size;
(2) Contacting the grind produced by step a) with an alcohol;
(3) Mixing the grind and alcohol for a sufficient time period to form a mixture;
(4) Sonicating the mixture;
(5) Centrifuging the mixture; and
(6) Collecting the alcohol extract in a suitable container.

### Claim 19 (depends on 18)

A product produced from the process of claim 18.

### Claim 20 (depends on 10)

A kit comprising the dosage form of claim 10 and instructions for use.
